Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Sit and Strengthen: Emsella Chair Your journey to total wellness includes more than skincare
Fu T, Xu Z, Liu L, Guo Q, Wu H, Liang X, et al
Learn about commonly prescribed drugs for type 2 diabetes
Cardiovascular Outcomes# EXSCEL Trial (Exenatide)# The EXSCEL trial (Holman et al., NEJM 2017) enrolled 14,752 patients with type 2 diabetes (73.1% with prior cardiovascular disease) and followed them for a median of 3.2 years: Primary MACE endpoint : HR 0.91 (95% CI 0.83-1.00), p=0.06 for superiority Met non-inferiority but narrowly missed superiority (p=0.06) All-cause mortality was reduced by 14% (HR 0.86, p=0.016) in a secondary analysis EXSCEL confirmed cardiovascular safety but did not prove cardiovascular benefit -- a critical distinction
Track Progress Beyond the Scale Focusing only on the scale creates frustration because weight loss is not linear
US$ 20.54
US$ 20.70
US$ 25.67
US$ 25.14
US$ 25.94
US$ 25.15
US$ 26.89
